We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News

Executive Summary

Accumetrics has CE marked its VerifyNow P2Y12 test for the identification of poor responders to antiplatelet therapy. Patients who do not respond well to antiplatelet drugs, which inhibit the P2Y12 receptor and therefore blood clotting, are at greater risk for future cardiovascular events.